A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

NCT02018874 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors and Non-Hodgkin's Lymphoma

Interventions

DRUG: LY2780301
DRUG: Gemcitabine

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris